Clinical Trials Browser

Recruiting × INDUSTRY × capmatinib × Clear all

NCT05703516 2026-06-01

A Post Approval Commitment Study on Tabrecta® (Capmatinib) in South Korea

Adenocarcinoma of Lung, Carcinoma, Non-Small-Cell Lung, Lung Neoplasms